euportal twitter euportal facebook

Europe’s full potential for the production of COVID-19 vaccines

COVID -19

29.3.2021 – The Commission is hosting the first pan-European matchmaking event with over 300 participating companies from 25 Member States to expand COVID-19 vaccine production capacities across Europe and address production and supply chain bottlenecks. The event aims to speed up connections between vaccine producers and service companies such as contract development and manufacturing organisations, [...]

Read more

A conditional marketing authorisation (CMA) for the COVID‑19 vaccine by BioNTech and Pfizer

health workers korona

21.12.2020 – Today, the European Commission has granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine developed by BioNTech and Pfizer, making it the first COVID-19 vaccine authorised in the EU. This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the [...]

Read more

Contract with a pharmaceutical company entered into force

EC logo

18.9.2020 – Today, a second contract with a pharmaceutical company entered into force following the contract’s formal signature between Sanofi-GSK and the Commission. The contract will allow all EU Member States to purchase up to 300 million doses of the Sanofi-GSK vaccine. Moreover, Member States may donate reserved doses to lower- and middle-income countries. Sanofi [...]

Read more

EC will purchase COVID -19 vaccine

COVID -19

25.8.2020 – The European Commission has today concluded exploratory talks with Moderna to purchase a potential vaccine against COVID-19. Moderna is the fifth company with which the Commission has concluded talks, following Sanofi-GSK on 31 July, Johnson & Johnson on 13 August, CureVac on 18 August, in addition to the signature of an Advance Purchase [...]

Read more